SGLT-2 inhibitors

GLP-1 Receptor Agonists Show Lower Heart Failure Risk Versus DPP-4 Inhibitors in Type 2 Diabetes

By MedXY 05/02/2026

New research comparing diabetes medications reveals GLP-1 receptor agonists lower heart failure hospitalization risk compared to DPP-4 inhibitors, while showing similar risk to SGLT-2 inhibitors in type 2 diabetes patients.

Diabetes & Endocrinology Internal Medicine news

Beyond Glucose: SGLT-2 Inhibitors and GLP-1 Receptor Agonists Slow Frailty Progression in Older Adults

By MedXY 12/30/2025

A large-scale Medicare study suggests that SGLT-2 inhibitors and GLP-1 receptor agonists significantly slow frailty progression in older adults with type 2 diabetes, independent of their cardiovascular benefits, marking a potential shift in geriatric diabetes management.

Diabetes & Endocrinology news Rheumatology

SGLT-2 Inhibitors and Autoimmune Rheumatic Disease Risk Reduction in Type 2 Diabetes: Insights from a Korean Nationwide Cohort

By MedXY 10/31/2025

A large South Korean cohort study suggests that sodium-glucose cotransporter-2 (SGLT-2) inhibitors reduce the incidence of autoimmune rheumatic diseases by 11% compared to sulfonylureas in adults with type 2 diabetes, indicating potential immunomodulatory benefits of SGLT-2 inhibitors beyond glycemic control.